TERAPI3.: Protection of Intellectual Property rights of new therapeutic agents against amyloid transthyretin diseases: AT09 technology. (Q2866989)

From EU Knowledge Graph
Revision as of 11:41, 20 January 2022 by DG Regio (talk | contribs) (‎Changed label, description and/or aliases in es, and other parts: Adding Spanish translations)
Jump to navigation Jump to search
Project Q2866989 in Portugal
Language Label Description Also known as
English
TERAPI3.: Protection of Intellectual Property rights of new therapeutic agents against amyloid transthyretin diseases: AT09 technology.
Project Q2866989 in Portugal

    Statements

    0 references
    25,000.0 Euro
    0 references
    50,000.0 Euro
    0 references
    50.0 percent
    0 references
    15 December 2017
    0 references
    14 December 2020
    0 references
    BSIM THERAPEUTICS, S.A.
    0 references
    Q2988326 (Deleted Item)
    0 references

    40°21'55.76"N, 8°39'29.95"W
    0 references
    O projeto TERAPI3 visa a proteção dos direitos de Propriedade Intelectual de uma nova classe de agentes terapêuticos contra doenças raras, nomeadamente doenças amiloides de transtirretina. Estes novos compostos são pequenas moléculas pertencentes à série química AT09 desenvolvida pela BSIM2. (Portuguese)
    0 references
    The TERAPI3 project aims to protect the intellectual property rights of a new class of therapeutic agents against rare diseases, namely transthyretin amyloid diseases. These new compounds are small molecules belonging to the AT09 chemical series developed by BSIM2. (English)
    7 July 2021
    0 references
    Le projet TERAPI3 vise à protéger les droits de propriété intellectuelle d’une nouvelle classe d’agents thérapeutiques contre les maladies rares, à savoir les maladies amyloïdes de la transthyrétine. Ces nouveaux composés sont de petites molécules appartenant à la série chimique AT09 développée par BSIM2. (French)
    4 December 2021
    0 references
    Das Projekt TERAPI3 zielt darauf ab, die Rechte des geistigen Eigentums einer neuen Klasse von therapeutischen Wirkstoffen gegen seltene Krankheiten, nämlich Transthyretin-Amyloiderkrankungen, zu schützen. Bei diesen neuen Verbindungen handelt es sich um kleine Moleküle der von BSIM2 entwickelten Chemikalie AT09. (German)
    13 December 2021
    0 references
    Het TERAPI3-project heeft tot doel de intellectuele eigendomsrechten van een nieuwe klasse van therapeutische middelen te beschermen tegen zeldzame ziekten, namelijk transthyretine amyloïdenziekten. Deze nieuwe verbindingen zijn kleine moleculen die behoren tot de AT09 chemische serie ontwikkeld door BSIM2. (Dutch)
    18 December 2021
    0 references
    Il progetto TERAPI3 mira a proteggere i diritti di proprietà intellettuale di una nuova classe di agenti terapeutici contro le malattie rare, vale a dire le malattie amiloidi transtiretina. Questi nuovi composti sono piccole molecole appartenenti alla serie chimica AT09 sviluppata da BSIM2. (Italian)
    17 January 2022
    0 references
    El proyecto TERAPI3 tiene por objeto proteger los derechos de propiedad intelectual de una nueva clase de agentes terapéuticos contra las enfermedades raras, a saber, las enfermedades amiloideas transtiretina. Estos nuevos compuestos son pequeñas moléculas pertenecientes a la serie química AT09 desarrollada por BSIM2. (Spanish)
    20 January 2022
    0 references
    Cantanhede
    0 references

    Identifiers

    CENTRO-01-0247-FEDER-037867
    0 references